Short answer
Cardiff Oncology, Inc. (CRDF) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $41,000 (down 62.4% year over year) with net income of −$12M.
Q1 2026 key financials · XBRL
- Revenue
- $41,000
- −62.4% YoY
- Net income
- −$12M
- +8.1% YoY
- Operating margin
- -31341.5%
- EPS (diluted)
- −$0.18
- +10.0% YoY
Source: XBRL data from the Cardiff Oncology, Inc. (CRDF) Q1 2026 10-Q on SEC EDGAR. USD.
Cardiff Oncology, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes from Form 10-K risk factors for year ended December 31, 2025
- Separation agreements with Mark Erlander and James Levine dated March 27, 2026
- No director or officer Rule 10b5-1 trading arrangements adopted or terminated during quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cardiff Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.